PMID- 23829867
OWN - NLM
STAT- MEDLINE
DCOM- 20131126
LR  - 20211021
IS  - 1349-7006 (Electronic)
IS  - 1347-9032 (Print)
IS  - 1347-9032 (Linking)
VI  - 104
IP  - 10
DP  - 2013 Oct
TI  - Phase II study of personalized peptide vaccination for refractory bone and soft 
      tissue sarcoma patients.
PG  - 1285-94
LID - 10.1111/cas.12226 [doi]
AB  - Refractory bone and soft tissue sarcomas are challenging diseases to treat 
      because of their robustness to chemotherapy. Although cancer vaccines have the 
      potential to become an attractive treatment modality, their progress has been 
      hampered by the presence of many subtypes of sarcomas and different human 
      leukocyte antigen (HLA)-types. We investigated whether personalized peptide 
      vaccination (PPV) would be feasible for the vast majority of sarcoma patients. 
      Twenty refractory bone and soft tissue sarcoma patients with nine different 
      subtypes and 11 different HLA-class IA phenotypes were enrolled in this study. A 
      maximum of four HLA-matched peptides showing higher peptide-specific IgG 
      responses in pre-vaccination plasma were selected from 31 pooled peptide 
      candidates applicable for the HLA-A2, -A3, -A11, -A24, -A26, -A31, and -A33 
      types, and were subcutaneously administered weekly for 6 weeks and bi-weekly 
      thereafter. Measurement of peptide-specific CTL and IgG responses along with 
      other laboratory analyses were conducted before and after vaccination. No 
      patients were excluded by either sarcoma subtypes or different HLA-types. No 
      severe adverse events associated with PPV were observed in any patients. 
      Peptide-specific immunological boosting was observed in the post-vaccination 
      samples from the majority of patients. Tumor reduction of the lung metastasis and 
      a long stable disease was observed in each case, and the median overall survival 
      time of the 20 cases was 9.6 months. Taken together, PPV could be feasible for 
      the vast majority of refractory sarcoma patients because of the safety and higher 
      rates of immunological responses regardless of the presence of different sarcoma 
      subtypes and various HLA-types.
CI  - (c) 2013 Japanese Cancer Association.
FAU - Takahashi, Ryuji
AU  - Takahashi R
AD  - Department of Surgery, Kurume University School of Medicine, Kurume, Japan.
FAU - Ishibashi, Yukinao
AU  - Ishibashi Y
FAU - Hiraoka, Koji
AU  - Hiraoka K
FAU - Matsueda, Satoko
AU  - Matsueda S
FAU - Kawano, Kouichirou
AU  - Kawano K
FAU - Kawahara, Akihiko
AU  - Kawahara A
FAU - Kage, Masayoshi
AU  - Kage M
FAU - Ohshima, Koichi
AU  - Ohshima K
FAU - Yamanaka, Ryuya
AU  - Yamanaka R
FAU - Shichijo, Shigeki
AU  - Shichijo S
FAU - Shirouzu, Kazuo
AU  - Shirouzu K
FAU - Itoh, Kyogo
AU  - Itoh K
FAU - Sasada, Tetsuro
AU  - Sasada T
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130806
PL  - England
TA  - Cancer Sci
JT  - Cancer science
JID - 101168776
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Cytokines)
RN  - 0 (HLA Antigens)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Vaccines, Subunit)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antigens, Neoplasm/analysis
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Bone Neoplasms/drug therapy/immunology/*therapy
MH  - Cancer Vaccines/adverse effects/*therapeutic use
MH  - Combined Modality Therapy
MH  - Cytokines/blood
MH  - Female
MH  - Gastrointestinal Diseases/chemically induced
MH  - HLA Antigens/analysis
MH  - Hematologic Diseases/chemically induced
MH  - Humans
MH  - Immunoglobulin G/blood
MH  - *Immunotherapy, Active/adverse effects
MH  - Kaplan-Meier Estimate
MH  - Middle Aged
MH  - Precision Medicine
MH  - Salvage Therapy
MH  - Sarcoma/drug therapy/immunology/*therapy
MH  - Soft Tissue Neoplasms/drug therapy/immunology/*therapy
MH  - T-Lymphocytes, Cytotoxic/immunology
MH  - Treatment Outcome
MH  - Vaccination
MH  - Vaccines, Subunit/adverse effects/therapeutic use
MH  - Young Adult
PMC - PMC7656559
EDAT- 2013/07/09 06:00
MHDA- 2013/12/16 06:00
PMCR- 2013/10/01
CRDT- 2013/07/09 06:00
PHST- 2013/03/07 00:00 [received]
PHST- 2013/06/28 00:00 [revised]
PHST- 2013/06/30 00:00 [accepted]
PHST- 2013/07/09 06:00 [entrez]
PHST- 2013/07/09 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
PHST- 2013/10/01 00:00 [pmc-release]
AID - CAS12226 [pii]
AID - 10.1111/cas.12226 [doi]
PST - ppublish
SO  - Cancer Sci. 2013 Oct;104(10):1285-94. doi: 10.1111/cas.12226. Epub 2013 Aug 6.